Destiny Pharma plc

Equities

DEST

GB00BDHSP575

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:20 05/07/2024 BST			5-day change	1st Jan Change
8.5 ^GBX	0.00%		-2.86%	-87.86%

06-18	Destiny Pharma presents "exciting" data for ringworm drug	AN
06-12	EARNINGS AND TRADING: Intuitive Investments NAV rises, talks up Hui10	AN

Destiny Pharma "making real progress"

March 08, 2023 at 01:21 pm

(via NewsDirect)

Destiny Pharma PLC (AIM:DEST) chief executive Neil Clark updates Proactive's Thomas Warner on the latest news from the clinical-stage biotech company.

The update follows the announcement that Destiny has reached a collaboration and co-development agreement for its phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence.

Clark says Destiny Pharma is "making real progess" and delivering on its strategy.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Destiny Pharma plc

Destiny Pharma presents "exciting" data for ringworm drug	06-18	AN
EARNINGS AND TRADING: Intuitive Investments NAV rises, talks up Hui10	06-12	AN
EARNINGS AND TRADING: Chariot loss narrows; Destiny Pharma approval	06-11	AN
Destiny Pharma Wins UK Regulator's Innovation Passport Tag for Nasal Drug Candidate	06-11	MT
Destiny Pharma plc Receives Innovation Passport Designation by the UK MHRA for XF-73 Nasal for the Prevention of Post-Surgical Site Infections	06-11	CI
Norcros sells Johnson Tiles UK; Trifast trading well	04-25	AN
Transcript : Destiny Pharma plc, 2023 Earnings Call, Apr 25, 2024	04-25
AIM WINNERS & LOSERS: Kromek jumps 14% on US government contract	04-25	AN
Destiny Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
EARNINGS AND TRADING: STV raises holding in Two Cities Television	01-31	AN
Destiny Pharma to Advance Skin, Colon Infection Therapies After Positive Evaluations	01-31	MT
Destiny Pharma plc Announces Clinical Development Update Positive Results from XF-73 Dermal Safety Study	01-31	CI
Destiny Pharma seeks to capitalise on XF-73 market potential in 2024	01-04	AN
Destiny Pharma Says Talks Ongoing with Potential Partners for Nasal Asset	01-04	MT
Destiny Pharma celebrates study findings on "potent" flagship drug	17/10/23	AN
AIM WINNERS & LOSERS: Destiny Pharma posts "landmark" XF-73 data	17/10/23	AN
Destiny Pharma plc Announces the Publication of New Microbiological Data on Xf-73 (Exeporfinium Chloride), Its Leading Antibacterial Drug,In Frontiers in Cellular and Infection Microbiology	17/10/23	CI
Dianomi swings to loss; Epwin revenue up	20/09/23	AN
Earnings Flash (DEST.L) DESTINY PHARMA Reports H1 Loss GBX-3.10	20/09/23	MT
Destiny Pharma plc Reports Earnings Results for the Half Year Ended June 30, 2023	20/09/23	CI
MGC Pharmaceuticals granted psilocybin import permit	31/07/23	AN
Destiny Pharma plc Announces the Publication of New Data in the Journal Infection & Drug Resistance from A Study Evaluating the Pfficacy of Xf-73	31/07/23	CI
FTSE 100 Closes Tuesday Up 0.2% Lifted by Unilever, Miners	25/07/23	DJ
Destiny Pharma says former Chair Nigel Rudd return to role	25/07/23	AN
Former Destiny Pharma Chairman Reprises Role	25/07/23	MT

Chart Destiny Pharma plc

Duration

Period

More charts

Company Profile

Destiny Pharma plc is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA). The Companyâs earlier stage pipeline is focused on other indications including two, separate dermal programmes incorporating its XF platform. It is also collaborating with SporeGen on a novel SPOR-COV innate immune system boosting nasal spray for the prevention of COVID-19 and influenza.

Sector

Biotechnology & Medical Research

Calendar

18/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.085 GBP

Average target price

1.883 GBP

Spread / Average Target

+2,115.68%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DESTINY PHARMA PLC	-87.86%	10.43M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs